Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 52: 1693-1700, 2006. First published July 27, 2006; 10.1373/clinchem.2006.071613
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2006.071613v1
52/9/1693    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Span, P. N.
Right arrow Articles by Sweep, F. C.G.J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Span, P. N.
Right arrow Articles by Sweep, F. C.G.J.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Cancer Diagnostics (since 2002)
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2006;52:1693-1700.)
© 2006 American Association for Clinical Chemistry, Inc.

Cancer Diagnostics

Do the Survivin (BIRC5) Splice Variants Modulate or Add to the Prognostic Value of Total Survivin in Breast Cancer?

Paul N. Span1,a, Vivianne C.G. Tjan-Heijnen2, Joop J.T.M. Heuvel1, Jacques B. de Kok3, John A. Foekens4 and Fred C.G.J. Sweep1

1 Departments of Chemical Endocrinology;
2 Medical Oncology; and
3 Clinical Chemistry; Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
4 Department of Medical Oncology, Erasmus MC-Daniel den Hoed, Rotterdam, The Netherlands.

aAddress correspondence to this author at: 479 Department of Chemical Endocrinology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. Fax 3124-354-1484; e-mail p.span{at}ace.umcn.nl.

Background: A total of 4 additional splice variants (survivin-{Delta}Ex3, survivin 2{alpha}, survivin-2B, and survivin-3B) have been described for survivin [baculoviral IAP repeat-containing protein (BIRC-5), approved gene symbol BIRC5], which has been implicated in both inhibition of apoptosis and regulation in mitosis in many tumor types. In this study, we assessed whether the survivin splice variants modulate or add to the prognostic value of total survivin in breast cancer.

Methods: With quantitative reverse transcription-PCR, we measured mRNA concentrations of survivin and all variants in tumor tissue from 275 patients with breast cancer and associated these with clinicopathologic characteristics and relapse-free survival.

Results: Total survivin, survivin-{Delta}Ex3, and survivin 2{alpha} mRNA levels were associated with young age and ductal histology. Total survivin and survivin-{Delta}Ex3 were highest in samples with advanced histological grade, whereas patients with 4–9 involved lymph nodes expressed less survivin-2B mRNA than those with 1–3 involved nodes. All variants were higher in tumors negative for steroid hormone receptors. Total survivin, survivin 2{alpha}, and survivin-3B were associated with poor relapse-free survival in univariate analyses. Survivin 2{alpha} and survivin-3B added to the prognostic value of total survivin in multivariate analyses. In addition, the prognostic value of total survivin was evident only in the presence of higher expression levels of these 2 variants.

Conclusions: All variants of survivin exhibited particular associations with clinicopathologic characteristics (age, histology, grade, and steroid hormone receptor status) of breast cancer patients. Survival analyses suggest a modulating role of survivin 2{alpha} and survivin-3B on the biological function of total survivin.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Cancer Res.Home page
Y. Ma, Y. Qian, L. Wei, J. Abraham, X. Shi, V. Castranova, E. J. Harner, D. C. Flynn, and L. Guo
Population-Based Molecular Prognosis of Breast Cancer by Transcriptional Profiling
Clin. Cancer Res., April 1, 2007; 13(7): 2014 - 2022.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.